3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
22
Myelodysplastic Syndromes
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia, Biphenotypic, Acute
6
Hodgkin Disease
6
Myeloproliferative Disorders
5
Burkitt Lymphoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Recurrence
3
Leukemia, Myelomonocytic, Chronic
3
Neuroblastoma
2
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Hematologic Neoplasms
2
Transplant-Related Hematologic Malignancy
1
Teratoma
1
Sarcoma
1
Rhabdomyosarcoma
1
Primary Myelofibrosis
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multi-centric Castleman's Disease
1
Macular dystrophy, corneal type 1
1
Interventions
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Granulocyte Colony-Stimulating Factor
×
90 days
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled